How many drugs treat Dyspareunia?

Drug Landscape tracks 6 marketed treatments for Dyspareunia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/dyspareunia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Dyspareunia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dyspareunia (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Dyspareunia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Osphena	OSPEMIFENE	Duchesnay	Estrogen Agonist/Antagonist [EPC]	Estrogen receptor beta	2013-01-01
Synestrol	DIENESTROL	Johnson & Johnson	dienestrol	Estrogen receptor	1947-01-01
Premarin	Conjugated estrogens	Pfizer	Estrogen [EPC]	Estrogen receptor	1942-01-01
Premarin	Estrogens, Conjugated	Pfizer	Estrogen replacement therapy	Estrogen receptors (nuclear receptors)	1942-01-01
Intrarosa	Intrarosa	Center for Vulvovaginal Disorders		Corticosteroid-binding globulin, Beta-glucuronidase, Glucose-6-phosphate 1-dehydrogenase
Dehydroepiandrosterone	Dehydroepiandrosterone	National Institute of Dental and Craniofacial Research (NIDCR)		Corticosteroid-binding globulin, Beta-glucuronidase, Glucose-6-phosphate 1-dehydrogenase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Dyspareunia
· 1 drug in Dyspareunia
Center for Vulvovaginal Disorders · 1 drug in Dyspareunia
Duchesnay · 1 drug in Dyspareunia
Johnson & Johnson · 1 drug in Dyspareunia
National Institute of Dental and Craniofacial Research (NIDCR) · 1 drug in Dyspareunia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Dyspareunia:

Cite this brief

Drug Landscape (2026). Dyspareunia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/dyspareunia. Accessed 2026-06-10.

Dyspareunia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing